Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Published:2020-04-17 Issue:6 Volume:95 Page:594-603
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Harrison Claire N.¹,Schaap Nicolaas²,Vannucchi Alessandro M.³,Kiladjian Jean‐Jacques⁴,Jourdan Eric⁵,Silver Richard T.⁶,Schouten Harry C.⁷,Passamonti Francesco⁸^ORCID,Zweegman Sonja⁹,Talpaz Moshe¹⁰,Verstovsek Srdan¹¹,Rose Shelonitda¹²,Shen Juan¹²,Berry Tymara¹²,Brownstein Carrie¹²,Mesa Ruben A.¹³

Affiliation:

1. Guyʼs and St Thomasʼ Hospital London UK

2. Radboud University Nijmegen Medical Centre Nijmegen The Netherlands

3. AOU CareggiUniversity of Florence Florence Italy

4. Hôpital Saint‐LouisUniversité de Paris; Inserm Paris France

5. Hématologie CliniqueInstitut de Cancérologie du Gard Nîmes France

6. Weill Cornell Medical College New York New York USA

7. University Hospital Maastricht Maastricht The Netherlands

8. University of Insubria Varese Italy

9. Amsterdam UMCVrije Universiteit Amsterdam Amsterdam Netherlands

10. University of Michigan Comprehensive Cancer Center Ann Arbor Michigan USA

11. MD Anderson Cancer Center Houston Texas USA

12. Celgene Corporation Summit New Jersey USA

13. University of Texas Health Science Center at San Antonio San Antonio Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25777

Reference41 articles.

1. Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management

2. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

3. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

4. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial;The Lancet Haematology;2024-09

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis;Blood Advances;2024-08-28

4. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group;Leukemia;2024-07-09

5. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3